Customize your JAMA Network experience by selecting one or more topics from the list below.
1 figure omitted
In 2003, approximately 37% of pregnant women in Botswana (2001 population:
1.7 million; approximately 40,000 births per year)1 were
infected with human immunodeficiency virus (HIV).2 Since
2001, all prenatal clinics in Botswana have offered HIV screening and interventions
for prevention of mother-to-child transmission of HIV (PMTCT), which can decrease
vertical transmission of HIV from 35%-40% to 5%-10%.3 Historically,
HIV testing in Botswana has been performed after individual pretest counseling,
with patients actively choosing whether to be tested (i.e., an “opt-in”
approach). In 2003, 52% of pregnant women receiving prenatal care nationwide
learned their HIV status. In 2004, to increase use of free national PMTCT
and antiretroviral treatment (ARV) programs, Botswana began routine, noncompulsory
(i.e., “opt-out”) HIV screening in prenatal and other health-care
settings. Concerns have been raised that routine testing in Africa might deter
women from seeking prenatal care and might result in fewer women returning
for their test results and HIV care after testing. To assess the early impact
of routine testing on HIV-test acceptance and rates of return for care, the
CDC Global AIDS Program and the PMTCT program in Botswana evaluated routine
prenatal HIV testing at four clinics in Francistown, the second largest city
in Botswana, where HIV prevalence has been ≥40% since 1995. This report
describes the results of that assessment, which indicated that, during February-April
2004, the first 3 months of routine testing, 314 (90.5%) of 347 pregnant women
were tested for HIV, compared with 381 (75.3%) of 506 women during October
2003–January 2004, the last 4 months of the opt-in testing period (p<0.001).
However, many women who were tested never learned their HIV status because
of logistical problems or not returning to the clinic. Substantial increases
in HIV testing of pregnant women were also observed at the Francistown referral
hospital and at prenatal clinics nationwide. These findings highlight the
potential public health impact of routine HIV testing with rapid, same-day
results for programs seeking to increase the number of persons with access
to HIV-prevention and treatment services.
In February 2004, in accordance with the new national policy of routine
HIV testing in Botswana, personnel in four selected clinics were trained in
a routine approach to prenatal HIV testing. Under the new system, existing
PMTCT counselors (secondary-school graduates with 4 weeks of HIV-counseling
training) held 10- to 15-minute group education sessions with pregnant women,
using a flip chart as a discussion guide. The discussion focused on HIV transmission,
PMTCT, ARV therapy, and testing needed for all mothers and infants. Women
were informed that they would be routinely screened for HIV and other diseases.
All were informed of their right to refuse testing. Women who did not want
any of the tests were encouraged to discuss their concerns with the counselor.
Women who arrived for prenatal care when no group could be convened received
the same education individually. Women who did not refuse had blood drawn
for HIV testing, which was performed offsite by laboratory technicians. Women
usually received results and posttest counseling at their next scheduled prenatal
visit (normally 1 month later). Women who were tested received individual
posttest counseling, with a focus on PMTCT interventions for women who were
identified as HIV positive, and were advised regarding next steps in medical
care and psychosocial support.
Data on prenatal-care attendance, HIV test acceptance, and receipt of
HIV test results were collected from clinic logbooks for the 4 months before
the routine testing project began and for the first 3 months of routine testing.
The median number of women beginning prenatal care at all four clinics was
114 per month (range: 95-134 women) during the opt-in testing period and 130
(range: 97-154 women) during the routine testing period, with a total of 859
women beginning care during the period of data collection. Six women who were
known to be HIV positive before their first prenatal visit were excluded from
this analysis. The median time for HIV test results to return from the laboratory
was 19 days (range: 0-59 days).
Acceptance of HIV testing and receipt of test results increased (Figure)
after the introduction of routine testing. However, no difference was observed
in the percentage of women who were tested but did not receive results between
the opt-in and routine periods (29.4% versus 33.0%; p=0.29). Of all 639 women
for whom test results were available, 306 (47.9%) were HIV positive.
Data from other sources also indicated an increase in the number of
pregnant women learning their HIV status since routine testing began. Nyangabgwe
Referral Hospital in Francistown is the site of approximately 10% of Botswana’s
annual deliveries, serving women from Francistown (including the four clinics
involved in this project and eight other clinics where staff were trained
in routine testing by project staff) and surrounding rural areas. For women
who do not know their HIV status at delivery, routine testing is performed
on the postnatal ward. Data from postnatal ward logbooks indicated that the
percentage of women who delivered at Nyangabgwe Referral Hospital who knew
their HIV status at the time of discharge increased from 50% in 2003 to 76%
during the first 9 months of 2004. Data reported by all 24 health districts
to the national PMTCT program indicated that the percentage of women who delivered
in health facilities who knew their HIV status increased from 52% in 2003
to 69% during the first 6 months of 2004.
As a complement to routine HIV testing, the government of Botswana plans
to train HIV counselors in all health facilities to perform rapid, onsite
HIV testing. This measure should reduce the number of clients who are tested
but never receive results.
K Seipone, MD, Family Health Div, Botswana Ministry of Health; R Ntumy,
MBChB, M Smith, MPH, BOTUSA Project, Gaborone; H Thuku, MD, Francistown District
Health Team; L Mazhani, MD, Nyangabgwe Hospital, Francistown, Botswana. T
Creek, MD, N Shaffer, MD, PH Kilmarx, MD, Global AIDS Program, National Center
for HIV, STD, and TB Prevention, CDC.
Botswana has one of the greatest HIV burdens in the world. To improve
coverage and effectiveness for its national PMTCT and ARV programs, Botswana
recently adopted a national policy of routine HIV testing in prenatal and
other health-care settings. The findings in this report demonstrate that group
education and routine HIV testing were largely acceptable to this population
of pregnant women in Botswana. Approximately 90% of women had an HIV test,
and the introduction of routine testing did not lead to reductions in the
number of women attending prenatal care or the percentage receiving test results
compared with the opt-in period. Under both testing paradigms, many women
who were tested did not learn their HIV status because laboratory testing
was conducted offsite and results were not immediately available. Approximately
20% of women in Francistown never return to the clinic where they first seek
prenatal care (Francistown District Health Team, unpublished data, 2002).
Some women return but choose not to receive their results, and laboratory,
clerical, and staffing difficulties add to the number of women who do not
receive results during pregnancy.
Interventions to prevent mother-to-child transmission of HIV are effective
and safe,4 and HIV-infected women who know
their status can also receive life-sustaining ARV therapy. Without intervention,
35%-40% of HIV-positive women transmit HIV to their infants; however, drug
prophylaxis and formula feeding can reduce transmission to 5%-10%, and combination
ARV therapy can reduce transmission to <1%.3 For
these reasons, routine HIV testing has become the standard of care for pregnant
women in developed countries,5 where HIV seroprevalence
is relatively low. A routine approach to HIV testing has been rare in Africa,
where HIV prevalence is higher, stigma associated with an HIV diagnosis has
been a barrier to test acceptance, and large-scale PMTCT and ARV treatment
programs are only recently becoming available. As part of worldwide efforts
to expand access to PMTCT and ARV therapy, routine HIV testing of pregnant
women (with the right to refuse) is recommended in the 2004 joint United Nations
and World Health Organization policy statement on HIV testing.6
The findings in this report are subject to at least two limitations.
First, this project involved clinics that had substantially higher-than-average
testing acceptance even before implementation of the routine testing policy.
Project clinics reported 76% acceptance at a time when the national program
reported 52% acceptance; this was likely attributable to their highly committed
staff. Second, data are being collected but are not yet available to determine
whether women tested for HIV under the routine testing policy accept PMTCT
interventions at the same rate as women tested under an opt-in testing policy.
Introduction of routine HIV testing can improve HIV testing participation
and access to prevention and treatment services in prenatal and other clinical
settings. Use of same-day, rapid HIV testing can increase the impact of such
a strategy in settings in which patients might not receive results from offsite
Introduction of Routine HIV Testing in Prenatal Care—Botswana,
2004. JAMA. 2005;293(2):152–153. doi:10.1001/jama.293.2.152